Bührer, E., Glassee, N., Kicinski, M., Kennedy, O. J., Blank, C. U., Long, G. V., . . . Mandala, M. Prognostic and predictive value of gastric acid suppressants in the EORTC 1325/KEYNOTE-054 randomized phase III trial of pembrolizumab vs placebo in resected stage III melanoma. Elsevier.
Chicago Style (17th ed.) CitationBührer, Emanuel, et al. Prognostic and Predictive Value of Gastric Acid Suppressants in the EORTC 1325/KEYNOTE-054 Randomized Phase III Trial of Pembrolizumab Vs Placebo in Resected Stage III Melanoma. Elsevier.
MLA (9th ed.) CitationBührer, Emanuel, et al. Prognostic and Predictive Value of Gastric Acid Suppressants in the EORTC 1325/KEYNOTE-054 Randomized Phase III Trial of Pembrolizumab Vs Placebo in Resected Stage III Melanoma. Elsevier.
Warning: These citations may not always be 100% accurate.